What is NDC 51662-1457?

51662-1457 is the product NDC for Diltiazem Hci, Diltiazem hydrochloride 100 mg/1 injection, powder, lyophilized, for solution, listed with the FDA by HF Acquisition Co LLC, DBA HealthFirst. It has 2 package NDCs, shown above in 10- and 11-digit form.

HF Acquisition Co LLC, DBA HealthFirst, NDC labeler code 51662. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Diltiazem Hci?

1 other product NDC are listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Diltiazem Hci NDC 51662-1457 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)51662-1457Labeler and product segments. Claims need a package NDC.

Product NDC at billing width51662-1457Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
51662-1457-1	5166214570151662145701	1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, PATENT DELIVERY SYSTEM (51662-1457-1)Marketed from Dec 15, 2019
51662-1457-3	5166214570351662145703	10 POUCH in 1 CASE (51662-1457-3) / 1 VIAL, PATENT DELIVERY SYSTEM in 1 POUCH (51662-1457-2) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, PATENT DELIVERY SYSTEMMarketed from Dec 11, 2022

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Diltiazem Hci
Generic name (nonproprietary): diltiazem hci
Active ingredients: Diltiazem hydrochloride — 100 mg/1
Dosage form: Injection, Powder, Lyophilized, For solution
Route: Intravenous
Labeler: HF Acquisition Co LLC, DBA HealthFirstNDC labeler code 51662
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 075853
Marketing start: Dec 15, 2019
Listing expires: Dec 31, 2026
Other FDA classes: Calcium Channel Antagonists (Mechanism)Cytochrome P450 3A4 Inhibitors (Mechanism)
Identifiers: Product ID 51662-1457_132cd9f9-a36c-4e35-e063-6294a90aaa17SPL ID 132cd9f9-a36c-4e35-e063-6294a90aaa17SPL set ID 99c5813f-1ffe-0eaa-e053-2a95a90a751bRxCUI 1791240UNII OLH94387TE
Pharmacologic class: Calcium Channel Blocker

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N451662145701 followed by a unit qualifier and the quantity

Package 51662-1457-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Mar 8, 2024.

Indications (excerpt from the label)

INDICATIONS & USAGE Diltiazem Hydrochloride Injection or Diltiazem Hydrochloride for Injection are indicated for the following: Atrial Fibrillation or Atrial Flutter Temporary control of rapid ventricular rate in atrial fibrillation or atrial flutter. It should not be used in patients with atrial fibrillation or atrial flutter associated with an accessory bypass tract such as in Wolff-Parkinson-White (WPW) syndrome or short PR syndrome. In addition, Diltiazem Hydrochloride Injection is indicated for: Paroxysmal Supraventricular Tachycardia Rapid conversion of paroxysmal supraventricular tachycardias (PSVT) to sinus rhythm. This includes AV nodal reentrant tachycardias and reciprocating tachy…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 51662-1457

What is NDC 51662-1457?: 51662-1457 is the product NDC for Diltiazem Hci, Diltiazem hydrochloride 100 mg/1 injection, powder, lyophilized, for solution, listed with the FDA by HF Acquisition Co LLC, DBA HealthFirst. It has 2 package NDCs, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Diltiazem Hci.
What is the active ingredient?: Diltiazem hydrochloride.
Who is the labeler?: HF Acquisition Co LLC, DBA HealthFirst, NDC labeler code 51662. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Diltiazem Hci?: 1 other product NDC are listed under this name. See all Diltiazem Hci NDCs.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other finished products listed under the same name: strengths, forms and labelers.

Other Diltiazem Hci NDCs
Product	Strength	Form · route	Labeler	Product NDC	Package NDCs (11-digit)
Diltiazem Hci	Diltiazem hydrochloride 5 mg/mL	InjectionIntravenous	HF Acquisition Co LLC, DBA HealthFirst	51662-1335	51662-1335-0151662-1335-02

Other NDCs under ANDA 075853

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 075853
Product	Strength	Form · route	Labeler	Product NDC
Diltiazem Hydrochloride	Diltiazem hydrochloride 100 mg/1	Injection, Powder, Lyophilized, For solutionIntravenous	Hospira, Inc.	0409-4350